Patents by Inventor Charles Prussak

Charles Prussak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AND VACCINES FOR USE IN TREATING ROR1 CANCERS AND INHIBITING METASTASIS
    Publication number: 20230110249
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Application
    Filed: March 16, 2022
    Publication date: April 13, 2023
    Inventors: Thomas James KIPPS, Jian YU, Bing CUI, Liguang CHEN, George F. WIDHOPF, Charles PRUSSAK
  • Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
    Patent number: 11312787
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: April 26, 2022
    Assignee: The Regents of the University of California
    Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George F. Widhopf, II, Charles Prussak
  • ANTIBODIES AND VACCINES FOR USE IN TREATING ROR1 CANCERS AND INHIBITING METASTASIS
    Publication number: 20190389962
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Application
    Filed: May 14, 2019
    Publication date: December 26, 2019
    Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George F. Widhopf, II, Charles Prussak
  • Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
    Patent number: 10344096
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: July 9, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George F. Widhopf, II, Charles Prussak
  • ANTIBODIES AND VACCINES FOR USE IN TREATING ROR1 CANCERS AND INHIBITING METASTASIS
    Publication number: 20180066063
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Application
    Filed: June 9, 2017
    Publication date: March 8, 2018
    Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George F. Widhopf, II, Charles Prussak
  • Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
    Patent number: 9758591
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 12, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George F. Widhopf, II, Charles Prussak
  • ANTIBODIES AND VACCINES FOR USE IN TREATING ROR1 CANCERS AND INHIBITING METASTASIS
    Publication number: 20150232569
    Abstract: The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ROR1 antibodies or antigen binding fragments, ROR1 binding peptides and ROR1 vaccines.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 20, 2015
    Inventors: Thomas James Kipps, Jian Yu, Bing Cui, Liguang Chen, George Widhopf, Charles Prussak
  • Novel chimeric TNF ligands
    Publication number: 20050048476
    Abstract: The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNF?, comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNF?, wherein the encoded domain or subdomain replaces a cleavage site of native TNF?, and a second nucleotide sequence encoding a domain or subdomain of native TNF? that binds to a TNF? receptor. The encoded chimeric TNF? is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNF? receptor on the surface of a cell. The chimeric TNF? is therefore useful in methods for inducing apoptosis of a cell expressing a TNF? receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNF? that is expressed on the surface of the cell.
    Type: Application
    Filed: December 6, 2001
    Publication date: March 3, 2005
    Inventors: Charles Prussak, Thomas Kipps, Mark Cantwell